Phthalazinone derivatives
    21.
    发明授权
    Phthalazinone derivatives 失效
    酞嗪衍生物

    公开(公告)号:US07902193B2

    公开(公告)日:2011-03-08

    申请号:US12271308

    申请日:2008-11-14

    摘要: A compound of the formula (I): wherein: A and B together represent an optionally substituted, fused aromatic ring; D is selected from: (i) where Y1 is selected from CH and N, Y2 is selected from CH and N, Y3 is selected from CH, CF and N; and (ii) where Q is O or S; RD is: wherein RN1 is selected from H and optionally substituted C1-10 alkyl; X is selected from a single bond, NRN2, CRC3RC4 and C═O; RN2 is selected from H and optionally substituted C1-10 alkyl; RC3 and RC4 are independently selected from H, R, C(═O)OR, where R is optionally substituted C1-10 alkyl, optionally substituted C5-20 aryl or optionally substituted C3-20 heterocyclyl; Y is selected from NRN3 and CRC1RC2. RC1 and RC2 are independently selected from H, R, C(═O)OR, where R is optionally substituted C1-10 alkyl, optionally substituted C5-20 aryl or optionally substituted C3-20 heterocyclyl; RC1 and RC2 together with the carbon atom to which they are attached may form an optionally substituted spiro-fused C5-7 carbocylic or heterocyclic ring; and when X is a single bond RN1 and RC2 may together with the N and C atoms to which they are bound, form an optionally substituted C5-7 heterocylic ring; and when X is CRC3RC4, RC2 and RC4 may together form an additional bond, such that there is a double bond between the atoms substituted by RC1 and RC3.

    摘要翻译: 式(I)的化合物:其中:A和B一起表示任选取代的稠合芳环; D选自:(i)其中Y1选自CH和N,Y2选自CH和N,Y3选自CH,CF和N; 和(ii)其中Q为O或S; RD是:其中RN1选自H和任选取代的C 1-10烷基; X选自单键NRN2,CRC3RC4和C = O; RN2选自H和任选取代的C 1-10烷基; RC3和RC4独立地选自H,R,C(= O)OR,其中R是任选取代的C 1-10烷基,任选取代的C 5-20芳基或任选取代的C 3-20杂环基; Y选自NRN3和CRC1RC2。 RC1和RC2独立地选自H,R,C(= O)OR,其中R是任选取代的C 1-10烷基,任选取代的C 5-20芳基或任选取代的C 3-20杂环基; RC1和RC2与它们所连接的碳原子一起可以形成任选取代的螺 - 稠合的C 5-7碳环或杂环; 当X是单键时,RN1和RC2可以与它们所结合的N和C原子一起形成任选被取代的C5-7杂环; 并且当X是CRC3RC4时,RC2和RC4可以一起形成附加键,使得在被RC1和RC3取代的原子之间存在双键。

    8-Quinolinxanthine and 8-isoquinolinxanthine derivatives as PDE 5 inhibitors
    24.
    发明申请
    8-Quinolinxanthine and 8-isoquinolinxanthine derivatives as PDE 5 inhibitors 失效
    8-喹啉黄嘌呤和8-异喹啉黄嘌呤衍生物作为PDE 5抑制剂

    公开(公告)号:US20060106214A1

    公开(公告)日:2006-05-18

    申请号:US11329889

    申请日:2006-01-11

    IPC分类号: A61K31/522 C07D473/04

    摘要: A compound of formula (I) R1 is hydrogen or alkyl optionally substituted by hydroxy, alkoxy, or alkylthio, R2 is hydrogen, alkyl, hydroxyalkyl, alkylcarbonyloxyalkyl, alkoxyalkyl, alkylthioalkyl, alkenyl, cycloalkylalkyl, heterocyclylalkyl, aralkyl in which the aryl ring thereof is optionally fused to a 5-membered heterocyclic group or is optionally substituted by one or more substituents selected from alkoxy, amino, alkylamino, dialkylamino, acylamino, halogen, hydroxy, aminosulfonyl, alkylaminosulfonyl, dialkylaminosulfonyl, alkylsufonylamino or dialkylaminosulfonylamino, R3 is hydrogen or alkyl optionally substituted by hydroxy, alkoxy, or alkylthio, R4 is hydrogen or alkyl, R5 is a quinolinyl, isoquinolinyl or oxodihydroisoquinolinyl group optionally fused to a 5-membered heterocyclic group and optionally substituted by one or more substituents selected from halogen, cyano, hydroxy, alkyl, hydroxyalkyl, alkoxyalkyl, alkylthioalkyl, alkoxy, alkylthio, alkenyl, alkoxycarbonyl, alkynyl, carboxyl, acyl, a group of formula —N(R6)R7, aryl optionally substituted by one or more substituents selected from halogen or alkoxy, or heteroaryl having 5 or 6 ring atoms attached through a ring carbon atom to the indicated carbon atom, and R6 and R7 are each independently hydrogen or alkyl optionally substituted by hydroxy or alkoxy or one of R6 and R7 is hydrogen and the other is acyl, or R6 and R7 together with the nitrogen atom to which they are attached denote a 5- or 6- membered heterocyclyl group.

    摘要翻译: 式(I)R 1的化合物是氢或任选被羟基,烷氧基或烷硫基取代的烷基,R 2是氢,烷基,羟基烷基,烷基羰氧基烷基,烷氧基烷基, 烷基硫代烷基,烯基,环烷基烷基,杂环基烷基,芳烷基,其中其芳基环任选地与5元杂环基稠合,或任选被一个或多个选自烷氧基,氨基,烷基氨基,二烷基氨基,酰氨基,卤素,羟基, 氨基磺酰基,烷基氨基磺酰基,二烷基氨基磺酰基,烷基磺酰基氨基或二烷基氨基磺酰基氨基,R 3是氢或任选被羟基,烷氧基或烷硫基取代的烷基,R 4是氢或烷基,R 0 任选地与5元杂环基稠合并且任选地被一个或多个选自卤素,氰基,羟基,烷基,羟基烷基,烷氧基烷基,烷基硫基的取代基取代的喹啉基,异喹啉基或氧代二氢异喹啉基 烷基,烷硫基,烯基,烷氧基羰基,炔基,羧基,酰基,式-N(R 6)R 7的基团,任选地被一个或多个 选自卤素或烷氧基的取代基或具有5或6个环原子通过环碳原子连接到指定碳原子的杂芳基,R 6和R 7各自独立地 任选被羟基或烷氧基取代的氢或烷基或R 6和R 7中的一个是氢,另一个是酰基或R 6和 R 7与它们所连接的氮原子一起表示5-或6-元杂环基。

    Method for preparing lattice-inserted titanium zeolites, and use thereof
    25.
    发明授权
    Method for preparing lattice-inserted titanium zeolites, and use thereof 失效
    晶格插入钛沸石的制备方法及其用途

    公开(公告)号:US06063944A

    公开(公告)日:2000-05-16

    申请号:US195

    申请日:1998-05-04

    摘要: A method is provided for preparing fully lattice-inserted titanium zeolites by post-synthesis processing of the synthetic zeolite optionally containing titanium with an inorganic acid, wherein the post-synthesis processing comprises processing the zeolite in the presence of at least one titanium source with a solution containing at least one oxidizing inorganic acid having a higher redox potential than an acidic tetravalent titanium solution. The invention is also directed to the use of the zeolites.

    摘要翻译: PCT No.PCT / FR96 / 01209 Sec。 371日期:1998年5月4日 102(e)日期1998年5月4日PCT提交1996年7月31日PCT公布。 出版物WO97 / 05060 日期1997年2月13日提供了一种用于通过后处理合成沸石制备完全晶格插入的钛沸石的方法,所述合成沸石任选地含有钛与无机酸,其中后合成工艺包括在至少存在下处理沸石 一种钛源与含有至少一种具有比酸性四价钛溶液更高的氧化还原电位的氧化性无机酸的溶液。 本发明还涉及沸石的用途。